Juggernaut deals within the med-tech space are often few and far between, but on Wednesday, the latest occurred when Hill-Rom (Chicago) revealed its intent to acquire Welch Allyn (Skaneateles Falls, New York) for about $2.05 billion. Hill-Rom will dole out about $1.625 billion in cash and about 8.1 million newly-issued shares of its common stock as payment for privately-held Welch Allyn.

Roswell Park Cancer Institute (RPCI; Buffalo, New York) is taking a more tailored approach with cancer therapy through the formation of its spin-out company, OmniSeq (also Buffalo). The company, which is fueled by $20 million worth of funding from RPCI, will focus on a collaborative approach to genomic diagnostics – matching cancer patients to specifically tailored therapies. Initially the company will focus on lung cancer.

Glaukos (Laguna Hills, California) has priced what analysts of the minimally invasive glaucoma surgical space (MIGS) are calling a very aggressive initial public offering (IPO). The company reported the pricing of 5,358,000 million shares of its common stock at $13 to $15 per share. If successful the company could net more than $75 million from the public offering. At the midpoint of the proposed range, Glaukos would command a fully diluted market value of $474 million.